Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: Adecto Pharmaceuticals, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis

    SBC: Stemsynergy Therapeutic            Topic: 102

    DESCRIPTION provided by applicant The tumor suppressor Adenomatous Polyposis Coli APC directs degradation of catenin a central signaling protein in the WNT pathway Germline loss of function mutations in APC activate WNT signaling and underlie the inherited colorectal cancer predisposition syndrome Familial Adenomatous Polyposis FAP an orphan disease while somatic mutations lead to spo ...

    STTR Phase I 2016 Department of Health and Human Services
  3. Nanoparticle Delivery System for Ewing Sarcoma Treatment

    SBC: NanoValent Pharmaceuticals, Inc.            Topic: 102

    DESCRIPTION provided by applicant This Phase I STTR project seeks to demonstrate proof of principle that novel targetable nanoparticles can delivery therapeutic substances to human tumor cells and reduce tumor burden in metastatic cancer The concept for these nanoparticles is based on the polymerized liposome nanoparticle PLN that displays functional antibodies that target tumor cell surfac ...

    STTR Phase I 2016 Department of Health and Human Services
  4. Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain

    SBC: On Target Therapeutics, LLC            Topic: 106

    DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...

    STTR Phase I 2016 Department of Health and Human Services
  5. Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions

    SBC: NanoValent Pharmaceuticals, Inc.            Topic: NIGMS

    DESCRIPTION provided by applicant The long term goal of this Phase I STTR project is to develop a commercially viable ultrasound contrast reagent UCR that will allow the noninvasive identification of newly forming abdominal adhesions after surgery Successful implementation would have significant impact because we would remove the impediment to clinical testing of anti adhesion therapies and ...

    STTR Phase I 2016 Department of Health and Human Services
  6. Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids

    SBC: Giner, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant Non Invasive Highly Specific Detection of Oxytocin in Biological Fluids Oxytocin a neuropeptide hormone plays an important role in a variety of complex social behaviors including affiliation sexual behavior and aggression It is best known for its role to facilitate the birth process through induction of myometrial muscle contractions However recent studi ...

    STTR Phase I 2016 Department of Health and Human Services
  7. Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma

    SBC: Cyteir Therapeutics, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Discovery of alpha4beta2 Nicotinic Receptor Antagonists as Alcohol Abuse Medications

    SBC: ASSUAGE PHARMACEUTICALS, INC.            Topic: NIAAA

    PROJECT SUMMARY Alcohol addiction and disorders associated to excessive alcohol use are a serious public health problem in the United States and in other parts of the world Current pharmacotherapies for the treatment of these disorders show limited efficacy Preclinical and clinical findings point to nicotinic acetylcholine receptors nAChRs as an alternative promising target for the developmen ...

    STTR Phase I 2016 Department of Health and Human Services
  9. Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Human respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis

    SBC: Dermaxon LLC            Topic: NIAMS

    Project Summary Abstract DermaXon s project goal is to develop efficacious novel selective inhibitors of CYP A for the topical treatment of ichthyosis Congenital ichthyosis is a family of hereditary disorders of keratinization characterized by dry scaling skin that may be thickened or very thin impacting the quality of life of patients and their family members Currently there is no cure f ...

    STTR Phase I 2016 Department of Health and Human Services
US Flag An Official Website of the United States Government